Press Releases

« Back to news

LogicBio Therapeutics Strengthens Leadership Team with Key Appointments

May 2, 2018 at 12:00 PM EDT

Sandra Poole named chief operating officer

Paul Herzich named senior director of manufacturing

Cambridge, Mass., May 2, 2018 LogicBio Therapeutics, Inc., a genetic medicine company founded to develop safe and lasting treatments for children with life-threatening early onset diseases, today announced the appointment of Sandra Poole as chief operating officer, and Paul Herzich as senior director of manufacturing.

“I am very pleased to welcome Sandra and Paul to the LogicBio team,” said Fred Chereau, president and chief executive officer of LogicBio Therapeutics. “Sandra’s experience building and leading organizations, combined with her operational expertise in the development and manufacturing of biologics, adds critical leadership strength as we move towards clinical development. Paul’s deep expertise in gene and biologic manufacturing gives us an extremely strong team in one of the most important areas for a genetic medicine company.”

Ms. Poole brings over 25 years of combined product and technology development, manufacturing, strategic alliances and general management experience in the biotechnology industry. Previously, she served as executive vice president, technical operations and commercial development at ImmunoGen, Inc. Prior to Immunogen, Ms. Poole spent more than 15 years at Genzyme in leadership roles of increasing responsibility, eventually rising to senior vice president of global biologics manufacturing. Ms. Poole is a member of the supervisory board of directors of Valneva SE. She holds a master’s and bachelor’s degree in Chemical Engineering from the University of Waterloo in Canada, is a licensed professional engineer and has completed the Executive Program in Business Management at the MIT Sloan School of Management. As chief operating officer, Ms. Poole will direct the company’s internal operations and help advance its robust portfolio of genome editing therapies.

“I am thrilled to be joining a rapidly emerging company with a novel platform and a mission to develop groundbreaking solutions for patients with severe genetic diseases,” said Ms. Poole.  “I look forward to working with Fred and the LogicBio team to move our lead candidate into the clinic as quickly as possible, while working with our partners to advance our portfolio of pipeline products.”

Mr. Herzich joins LogicBio from Pfizer’s Bamboo Therapeutics, where he served as director of clinical gene therapy manufacturing. In this role, Mr. Herzich managed facilities, compliance, and cGMP manufacturing of the company’s gene therapy products. Prior to Bamboo, he served as head of technical development manufacturing at Seqirus. Mr. Herzich holds an MBA from North Carolina State University and a bachelor’s degree in Biology from Rutgers University. In his new role as senior director of manufacturing, Herzich will establish and guide the development of manufacturing processes for LogicBio’s platform technology, GeneRide™.

“I look forward to working with this dedicated and driven team to build out LogicBio’s broad therapeutic pipeline and extend the benefits of genome editing to pediatric patients,” said Mr. Herzich.

About LogicBio Therapeutics

LogicBio Therapeutic is a genetic medicine company, founded to deliver the benefits of genome editing to the fight against early onset childhood diseases. Launched in 2016 by pioneers in gene therapy from Stanford University and funded by leading life science investors, LogicBio is developing a pipeline of safe and durable treatments for pediatric indications. Our core technology, GeneRide™, enables the site-specific integration of a therapeutic transgene, in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression. With a world-class global team headquartered in Cambridge, Massachusetts, LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

For more information, please visit


Media: Paul Goldsmith, Ten Bridge Communications